GLUE — Monte Rosa Therapeutics Share News
0.000.00%
Last trade - 00:00- $947.83m
- $326.73m
- $123.67m
Brief: Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Monte Rosa Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Monte Rosa Therapeutics Q2 revenue drops, net loss widens on higher R&D
Brief: Monte Rosa Therapeutics Q2 Collaboration Revenue USD 8.968 Million
U.S. STOCKS ON THE MOVE-GoDaddy, Amazon, Chevron
U.S. STOCKS ON THE MOVE-Apple, Reddit, Roblox
Monte Rosa tumbles on read-through from Novo's cardiovascular trial failure
Monte Rosa Therapeutics Q1 collaboration revenue drops 95%
Brief: Monte Rosa Therapeutics Q1 Net Income USD -44.503 Million
U.S. RESEARCH ROUNDUP- Ferguson Enterprises, Hartford Insurance Group, JP Morgan
Monte Rosa Therapeutics Q4 revenue drops, net loss widens on lower milestone payments
Brief: Monte Rosa Therapeutics Q4 Operating Income USD -49.715 Million
U.S. STOCKS ON THE MOVE-Customers Bancorp, Forgent Power Solutions, Nvidia
U.S. STOCKS ON THE MOVE-Dollar Tree, Micron, Customers Bancorp
U.S. STOCKS ON THE MOVE-Intuit, Acumen, Circle,
U.S. STOCKS ON THE MOVE-Sable Offshore, Nebius, Upstart
Brief: Monte Rosa Therapeutics Announces Clinical Supply Agreement To Support Phase 2 Trial Evaluating Mrt-2359 In Combination With Apalutamide For The Treatment Of Metastatic Castration-Resistant Prostate Cancer
Monte Rosa rises on lining up new combo trial in advanced prostate cancer
U.S. STOCKS ON THE MOVE-Intel, Gartner, Chipotle